SI-BONE Inc
NASDAQ:SIBN
SI-BONE Inc
Total Equity
SI-BONE Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SI-BONE Inc
NASDAQ:SIBN
|
Total Equity
$167m
|
CAGR 3-Years
7%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Equity
$25.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
17%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Equity
$21.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Equity
$20.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Equity
$47.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Equity
$16.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
SI-BONE Inc
Glance View
SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.
See Also
What is SI-BONE Inc's Total Equity?
Total Equity
167m
USD
Based on the financial report for Dec 31, 2024, SI-BONE Inc's Total Equity amounts to 167m USD.
What is SI-BONE Inc's Total Equity growth rate?
Total Equity CAGR 5Y
22%
Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for SI-BONE Inc have been 7% over the past three years , 22% over the past five years .
You don't have any saved screeners yet